Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against Omicron Subvariants
Immunome Inc (NASDAQ:IMNM) has announced that its cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in lab testing. IMM-BCP-01 is currently in Phase 1b testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5, and BA.2. Related: Immunome Shares Rise After Publishing Positive COVID-19 Antibody…
Benzinga ·
Benzinga
